TECHNICAL REPORT

HIV DRUG RESISTANCE REPORT 2021

NOVEMBER 2021

HIV DRUG RESISTANCE



NHO / Blink Media - Gareth Bent

TECHNICAL REPORT

HIV DRUG RESISTANCE REPORT 2021

NOVEMBER 2021

HIV DRUG RESISTANCE



HIV drug resistance report 2021

ISBN 978-92-4-003860-8 (electronic version) ISBN 978-92-4-003861-5 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).

Suggested citation. HIV drug resistance report 2021. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

CONTENTS

ACKNOWLEDGEMENTS ACRONYMS DEFINITIONS EXECUTIVE SUMMARY INTRODUCTION	iv iv v vi 1
 1. PRETREATMENT HIV DRUG RESISTANCE AMONG ADULTS INITIATING FIRST-LINE ART 1.1 SURVEY METHOD: PRETREATMENT HIV DRUG RESISTANCE AMONG ADULTS 1.2 PROGRESS IN IMPLEMENTING THE SURVEYS AND GEOGRAPHICAL REPRESENTATION 1.3 DATA ANALYSIS 1.4 POPULATIONS 1.5 KEY FINDINGS 1.6 IMPLICATIONS OF THE FINDINGS 	2 2 3 3 5 9
 2. PRETREATMENT HIV DRUG RESISTANCE AMONG INFANTS NEWLY DIAGNOSED WITH HIV 2.1 SURVEY METHOD: PRETREATMENT HIV DRUG RESISTANCE AMONG INFANTS NEWLY DIAGNOSED WITH HIV 2.2 PROGRESS IN IMPLEMENTING THE SURVEYS AND GEOGRAPHICAL REPRESENTATION 2.3 DATA ANALYSIS 2.4 POPULATIONS 2.5 KEY FINDINGS 2.6 IMPLICATIONS OF THE FINDINGS 	12 12 13 13 13 13
 3. REVIEW OF HIV DRUG RESISTANCE AMONG POPULATIONS RECEIVING PREP FOR PREVENTING HIV 3.1 SUMMARY OF THE PROBLEM 3.2 HIV DRUG RESISTANCE AMONG PEOPLE SEROCONVERTING ON ORAL PREP 3.3 HIV DRUG RESISTANCE IN WOMEN USING THE DPV VAGINAL RING 3.4 HIV DRUG RESISTANCE AMONG PEOPLE SEROCONVERTING ON CAB-LA PREP 3.5 PUBLIC HEALTH IMPLICATIONS OF PREP-ASSOCIATED RESISTANCE 3.6 WHO SURVEY METHOD FOR COUNTRIES SCALING UP PREP 	16 16 17 19 20 21 21
 4. ACQUIRED HIV DRUG RESISTANCE AMONG ADULTS AND CHILDREN AND ADOLESCENTS RECEIVING ART 4.1 SURVEY METHOD: ACQUIRED HIV DRUG RESISTANCE AMONG ADULTS AND CHILDREN AND ADOLESCENTS RECEIVING ART 4.2 PROGRESS IN IMPLEMENTING THE SURVEYS AND GEOGRAPHICAL REPRESENTATION 4.3 DATA ANALYSIS 4.4 POPULATIONS 4.5 KEY FINDINGS 4.6 IMPLICATIONS OF THE FINDINGS 	 22 22 23 23 23 29
 5. UPDATE ON PROGRESS IN IMPLEMENTING THE 2017-2021 GLOBAL ACTION PLAN ON HIV DRUG RESISTANCE 5.1 PROGRESS ON HIV DRUG RESISTANCE PREVENTION AND RESPONSE (STRATEGIC OBJECTIVE 1) 5.2 PROGRESS ON MONITORING AND SURVEILLANCE (STRATEGIC OBJECTIVE 2) 5.3 PROGRESS ON RESEARCH AND INNOVATION (STRATEGIC OBJECTIVE 3) 5.4 PROGRESS ON STRENGTHENING LABORATORY CAPACITY (STRATEGIC OBJECTIVE 4) 5.5 PROGRESS ON BUILDING SUSTAINABLE GOVERNANCE AND ENABLING MECHANISMS (STRATEGIC OBJECTIVE 5) 5.6 SUCCESSES AND CHALLENGES IN IMPLEMENTING THE GLOBAL ACTION PLAN ON HIV DRUG RESISTANCE 2017–2021 5.7 CONCLUSIONS 	 31 32 36 38 39 41 42 43
REFERENCES	44
ANNEX 1. COUNTRY-LEVEL TABLES ANNEX 2. METHODOLOGICAL NOTES	49 125

ACKNOWLEDGEMENTS

This technical report is the result of collaboration between the WHO Department of Global HIV, Hepatitis and STI Programmes and contributing member states.

Amalia Giron, Seth Inzaule, Neil Parkin and Michael Jordan (WHO consultants) analyzed and interpreted the data and wrote the report. The development of the document was led by the WHO Department of Global HIV, Hepatitis and STI Programmes, coordinated by Silvia Bertagnolio (before July 2021) and by Marco Vitoria (after July 2021) under the leadership of Meg Doherty.

Contributors included: **Martina Penazzato** (Global HIV, Hepatitis and STI Programmes) provided technical input and guidance. **Urvi Parikh** and **John Mellors** (University of Pittsburgh School of Medicine) wrote the section on HIV drug resistance among populations receiving pre-exposure prophylaxis for preventing HIV. **Paul Weiss** (WHO consultant) developed the aggregate analysis plan and developed code for the statistical pool analysis. **Kathleen Krupinski** (WHO consultant) developed the maps.

HIV drug resistance survey data were provided by participating national ministries of health with the support of WHO regional and country offices. The WHO HIVResNet Laboratory Network was essential in producing high-quality drug resistance surveillance data.

The following members of the WHO HIVResNet steering group performed external review: **Solange Baptiste, Mohamed Chakroun, John Mellors, Irene Mukui, Andrew Phillips and Jonathan Schapiro.** The following WHO regional advisors supported survey implementation: **Sandra Jones, Linh Le, Fausta Mosha, Giovanni Ravasi, B.B. Rewari,** and **Omar Sued**.

ACRONYMS AND ABBREVIATIONS

3TC	lamivudine
ABC	abacavir
ART	antiretroviral therapy
ARV	antiretroviral drug
ATV/r	atazanavir/ritonavir
BIC	bictegravir
САВ	cabotegravir
CI	confidence interval
DBS	dried blood spots
DPV	dapivirine
DRV/r	darunavir/ritonavir
DTG	dolutegravir
EFV	efavirenz
FTC	emtricitabine
INSTI	integrase strand-transfer inhibitor
NNRTI	non-nucleoside reverse-transcriptase inhibitor
NRTI	nucleoside reverse-transcriptase inhibitor
NVP	nevirapine

- **PEPFAR** United States President's Emergency Plan for AIDS Relief
- PI/r ritonavir-boosted protease inhibitor
- PrEP pre-exposure prophylaxis
- TDF tenofovir disoproxil fumarate
- TLD TDF in combination with 3TC and DTG as a fixed-dose combination
- TLE TDF in combination with 3TC and EFV as a fixed-dose combination
- ZDV zidovudine


DEFINITIONS

- ARV drug-naive applies to people with no history of ARV drug exposure.
- HIV drug resistance is caused by one or more changes (mutations) in the genetic structure of HIV that affect the ability of a specific drug or combination of drugs to block replication of HIV. All current ARV drugs, including newer classes, are at risk of becoming partly or fully inactive because of the emergence of drug-resistant virus. For the purpose of this report, HIV drug resistance was assessed using the Stanford HIVdb algorithm version 9.0, with virus predicted to have low-, intermediate- or high-level resistance categorized as resistant (penalty score ≥15). The following are the three main categories of HIV drug resistance.
 - **1. Acquired HIV drug resistance** develops when HIV mutations emerge because of viral replication among individuals receiving ARV drugs.
 - **2. Transmitted HIV drug resistance** occurs when individuals are infected with HIV that has drug resistance mutations.
 - **3. Pretreatment HIV drug resistance** refers to drug-resistant virus detected in ARV drug–naive individuals initiating ART or individuals with previous ARV drug exposure initiating or reinitiating first-line ART. Thus, for the purpose of this report, pretreatment HIV drug resistance is either transmitted or acquired resistance or both. Resistant virus may have been transmitted at the time of infection (transmitted HIV drug resistance) or may be selected (acquired HIV drug resistance) through previous ARV drug exposure (such as among women who received ARV drugs for the prevention of mother-to-child transmission of HIV, among people who have received pre-exposure prophylaxis or among individuals reinitiating first-line ART after a period of treatment interruption).
- NNRTI-based ART regimens are defined as regimens containing efavirenz or nevirapine for the purpose of this report.
- PI-based ART regimens are defined as regimens containing ritonavir-boosted atazanavir, ritonavir-boosted darunavir or ritonavir-boosted lopinavir for the purpose of this report.

EXECUTIVE SUMMARY

Antiretroviral therapy (ART) has been scaled up: at the end of 2020, 27.5 million people were receiving ART globally. However, HIV drug resistance can compromise the effectiveness of antiretroviral (ARV) drugs in reducing HIV incidence and HIV-associated morbidity and mortality. To minimize the emergence and transmission of drugresistant HIV, WHO recommends that ART and pre-exposure prophylaxis (PrEP) programmes be accompanied by measures to monitor the quality of ART and PrEP delivery and the routine surveillance of HIV drug resistance. Between 2004 and 2021, 66 countries implemented surveys of HIV drug resistance using WHO-recommended methods (**Map 1**). As of late 2021, 34 countries plan to conduct HIV drug resistance surveys during 2022–2024.

MAP 1. Implementation of national HIV drug resistance surveys, 2004–2021



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. Data Source: World Health Organization Map Production: WHO GIS Centre for Health, DNA/DDI Map Creation Date: **12 October 2021**



预览已结束, 完整报告链接和二维码如下:



https://www.yunbaogao.cn/report/index/report?reportId=5 23487